Where can I find the detailed Q1 2017 financial results for Beigene?

The detailed financial results for the three months ended March 31, 2017, are provided in the press release furnished as Exhibit 99.1 to this Form 8-K filing.

What is the significance of the information being 'furnished' rather than 'filed'?

Information that is 'furnished' in an 8-K, as opposed to 'filed,' is generally not subject to the same level of liability under Section 18 of the Securities Exchange Act of 1934, which pertains to misleading statements in filed documents. However, it is still considered material information for investors.

What does it mean that Beigene is an 'emerging growth company'?

An emerging growth company (EGC) is a company with total annual gross revenues of less than $1 billion during its most recently completed fiscal year. EGCs are afforded certain regulatory accommodations, including a longer phase-in period for new accounting standards, though Beigene has elected not to use this extended transition period.

Does this filing include any updates on Beigene's drug development pipeline or clinical trials?

This specific 8-K filing is primarily focused on announcing financial results. Any updates on the drug development pipeline or clinical trials would be detailed within the furnished press release (Exhibit 99.1) or potentially in other company communications.

ONC/BEIGF 8-K: Earnings & Results

Summary

Beigene, Ltd. (ONC) filed an 8-K on May 10, 2017, to announce its financial results for the first quarter ended March 31, 2017. The primary purpose of this filing is to furnish the press release detailing these results, as indicated by Item 2.02 and Item 9.01. Investors should note that the information furnished in this report, including the press release, is not considered "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 and thus does not carry the same liability implications. While the 8-K itself does not contain the detailed financial figures, it serves as a notification to the market that the company has released its quarterly earnings. Investors seeking specific details on BeiGene's performance, including revenue, net income/loss, and operational updates for Q1 2017, will need to refer to the furnished press release (Exhibit 99.1). The filing also confirms Beigene's status as an emerging growth company and its election not to use the extended transition period for new or revised accounting standards.

Key Highlights

1Beigene, Ltd. announced its Q1 2017 financial results on May 10, 2017.
2The 8-K filing primarily furnishes the press release containing the financial results.
3Investors must refer to Exhibit 99.1 (the press release) for detailed financial performance data for the quarter.
4Information furnished in this 8-K is not considered 'filed' under Section 18 of the Exchange Act.
5Beigene has elected not to use the extended transition period for new accounting standards.
6The filing confirms Beigene's status as an emerging growth company.

BeOne Medicines Ltd. 8-K Report, Financial Results (May 10, 2017)

Summary

Key Highlights

Frequently Asked Questions